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DOCK180 is the archetype of the DOCK180-family guanine nucleotide exchange factor for small GTPases Rac1 and
Cdc42. DOCK180-family proteins share two conserved domains, called DOCK homology region (DHR)-1 and -2. Al-
though the function of DHR2 is to activate Rac1, DHR1 is required for binding to phosphoinositides. To better understand
the function of DHR1, we searched for its binding partners by direct nanoflow liquid chromatography/tandem mass
spectrometry, and we identified sorting nexins (SNX) 1, 2, 5, and 6, which make up a multimeric protein complex
mediating endosome-to-trans-Golgi-network (TGN) retrograde transport of the cation-independent mannose 6-phosphate
receptor (CI-MPR). Among these SNX proteins, SNX5 was coimmunoprecipitated with DOCK180 most efficiently. In
agreement with this observation, DOCK180 colocalized with SNX5 at endosomes. The RNA interference-mediated
knockdowns of SNX5 and DOCK180, but not Rac1, resulted in the redistribution of CI-MPR from TGN to endosomes.
Furthermore, expression of the DOCK180 DHR1 domain was sufficient to restore the perturbed CI-MPR distribution in
DOCK180 knockdown cells. These data suggest that DOCK180 regulates CI-MPR trafficking via SNX5 and that this
function is independent of its guanine nucleotide exchange factor activity toward Rac1.
INTRODUCTION
DOCK180 was originally identified as one of two major
binding proteins of the adaptor protein CRK and became the
archetype of the DOCK180-family guanine nucleotide ex-
change factor (GEF) for Rac1 and Cdc42 (Hasegawa et al.,
1996; Cote and Vuori, 2002; Meller et al., 2002). Genetic
studies have identified orthologues of DOCK180 in Caeno-
rhabditis elegans (CED-5) and Drosophila melanogaster (Myo-
blast city, MBC), respectively, which make up an evolution-
arily conserved protein group called the CDM (CED-5,
DOCK180, MBC)-family (Wu and Horvitz, 1998). The crucial
role of these DOCK180-family proteins has been demon-
strated in various biological processes. In C. elegans, CED-5
acts in the engulfment of apoptotic cell corpses and in the
migration of gonadal distal tip cells (Wu and Horvitz, 1998).
MBC is necessary for myoblast fusion and dorsal closure
during the embryogenesis of D. melanogaster (Erickson et al.,
1997). Plasma membrane-targeted mammalian DOCK180 al-
ters the morphology of COS cells from spindled to flat and
polygonal shape, and coexpression of DOCK180 with both
CRKII and p130Cas induces the accumulation of these pro-
teins at the focal adhesions in NIH3T3 cells (Hasegawa et al.,
1996; Kiyokawa et al., 1998b).
DOCK180 contains N-terminal SH3 and C-terminal pro-
line-rich domains, which function as docking sites for ELMO
(Gumienny et al., 2001) and CRKII (Hasegawa et al., 1996),
respectively. Both ELMO and CRKII function to mediate
extracellular signals via RhoG (Katoh and Negishi, 2003)
and p130Cas (Kiyokawa et al., 1998a), respectively, and to
enhance DOCK180-induced Rac1 activation. In addition to
the SH3 and proline-rich domains, subsequent studies iden-
tified two other regions, designated DHR1 and DHR2 (or
CZH1 and CZH2/DOCKER, respectively) (Cote and Vuori,
2002; Meller et al., 2002), both of which showed high se-
quence homology among the 11 human DOCK180 super-
family proteins. A succession of evidence has demonstrated
that DHR2 functions as a guanine nucleotide exchange fac-
tor for Rho-family proteins (Fukui et al., 2001; Cote and
Vuori, 2002; Meller et al., 2002; Watabe-Uchida et al., 2006). It
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has been shown that a DOCK180 mutant without DHR1 fails
to promote cell migration, irrespective of its intact activity
toward Rac GTP loading (Cote et al., 2005). In vitro
data indicated that phosphatidylinositol 3,5-bisphosphate
[PI(3,5)P2] and phosphatidylinositol 3,4,5-trisphosphate
(PIP3) bind to DHR1 and that PIP3 recruits DOCK180
through DHR1 at the site of lamellipodia induced by plate-
let-derived growth factor (Cote et al., 2005).
Sorting nexins (SNXs) are cytoplasmic and membrane-
associated proteins that share a phox homology (PX)-do-
main, which recognizes various phosphoinositides (Teas-
dale et al., 2001). SNX1 was first identified as a binding
protein to epidermal growth factor receptor (EGFR) by yeast
two-hybrid screening, and it was found to enhance receptor
degradation when overexpressed (Kurten et al., 1996). A
comparison of amino acid sequences revealed that SNX1 is
an ortholog of a yeast protein called Vacuolar protein sort-
ing 5p (Vps5p) (Horazdovsky et al., 1997). Vps5p is a con-
stituent of the heteropentameric complex called retromer,
which consists of Vps35p, Vps29p, Vps26p, Vps5p, and
Vps17p, and regulates the endosome-to-Golgi transport of
proteins (Seaman et al., 1998). In yeast, newly synthesized
acidic hydrolases are sorted to vacuoles by hydrolase recep-
tor Vps10p (Seaman, 2005). After the delivery of hydrolase,
Vps10p is recycled back to the late Golgi apparatus. In
mammalian cells, the delivery of hydrolases from trans-
Golgi network (TGN) to lysosome is mediated by the man-
nose 6-phosphate receptors (MPRs) (Kornfeld and Mellman,
1989). There are two distinct MPRs in mammalian cells: the
46-kDa cation-dependent MPR (CD-MPR) and the 300-kDa
cation-independent MPR (CI-MPR). Neither MPR shares
any significant sequence homology with Vps10p but, like
Vps10p, both have an essentially identical function and cycle
between the TGN and the endosome (Seaman, 2005). The
small interfering RNA (siRNA)-mediated knockdown tech-
nique has shown that suppression of VPS26 and SNX1 in-
duces CI-MPR mislocalization to the peripheral vesicular
structure from TGN (Carlton et al., 2004; Seaman, 2004).
Recently, a siRNA-mediated loss-of-function screen for 30
SNX members identified SNX5 and SNX6 as functional
counterparts of Vps17p (Wassmer et al., 2007).
Here, we identify SNX5 as a binding partner of DHR1 of
DOCK180. Furthermore, we show a potential role of
DOCK180 in retromer-mediated retrograde transport of CI-
MPR, which is independent of the previously reported bind-
ing partners such as ELMO, CRK, and Rac1.
MATERIALS AND METHODS
Expression Plasmids
The cDNA encoding the full-length or truncated SNXs were amplified by
polymerase chain reaction (PCR) with primer sets containing XhoI or SalI
sequences at 5 terminus, and NotI at 3 terminus, and subcloned into pDrive
(QIAGEN, Hilden, Germany) or pCR2.1-TOPO vector (Invitrogen, Paisley,
United Kingdom). As the template for PCR, the plasmids (Teasdale et al.,
2001; Cozier et al., 2002; Carlton et al., 2005) or cDNA from HeLa cells was
used. After the nucleotide sequences were confirmed, the cDNAs were cloned
to pCAGGS-EGFP, pCXN2-GST, pCXN2-mRFP, or pCA-FLAG, generating
pCA-EGFP-SNX5, pCXN2-GST-SNX5, pCXN2-mRFP-SNX5, pCA-FLAG-
SNX1, -SNX2, -SNX4, -SNX5, -SNX6b (denoted as SNX6), -SNX5-PX (amino
acids 1-168), -SNX5-BAR (169-404), -SNX5-Helix1 (1-261), and -SNX5-Helix2
(1-343). Similarly, DHR1 domains of DOCK-family proteins are generated.
The following cDNAs were used as templates: pCA-FLAG-DOCK180 for
DOCK180 (Hasegawa et al., 1996), pGFP-DOCK2 for DOCK2 (Nishihara et al.,
1999), pCXN2-mRFP-DOCK4 for DOCK4 (Yajnik et al., 2003), and KIAA0299
for DOCK3, KIAA1395 for DOCK6, and KIAA1771 for DOCK9 (Kazusa DNA
Research Institute, Chiba, Japan). Full-length DOCK180 was inserted into
pCAGGS-EGFP and pCXN2-mVenus to generate pCA-EGFP-DOCK180 and
pCXN2-mVenus-DOCK180, respectively. The plasmids pCA-FLAG-ERK2 was
described previously (Fujioka et al., 2006). pCA-FLAG-mSos1 is the expression
plasmid for mouse Sos1 protein. To construct the rupture of a lens cataract (RLC)
mutant of human DOCK180, the DHR1 domain carrying the RLC deletion
mutant was first constructed. The RLC region, which corresponds to amino acids
488-496 of human DOCK180, was deleted by overlapping PCR. The first PCR
reactions were performed independently with primer set #1, SalI-DHR1F-F
(CACCGTCGACGGTGATGTTCGAAATGATATC) and RLC-del-DOCK1-R
(GTCCTCGATGGGAATGGCCAGCTTTACTTGGTAGTAAATCAC) and #2,
RLC-del-DOCK1-F (GTGATTTACTACCAAGTAAAGGTGGCCATTCCCATCG-
AGGAC) and DHR1stop-R-NotI (GGGCGGCCGCTCACTCCATCATGATGTT-
GAAGAG). The amplified DNA fragments were used as templates in the second
PCR with primers SalI-DHR1F-F and DHR1stop-R-NotI. The nucleotide sequences
of the second PCR product were confirmed after being cloned into pENTRY vector
(Invitrogen). The RLC cDNA fragment was cloned into pEBG to generate pEBG-
DHR1-RLC. After the full-length DOCK180-RLC was established in pBlueScript
vector, expression vector pCXN2-mVenus-DOCK180-RLC was constructed. pSu-
per.retro.puro vector (Oligoengine, Seattle, WA) was used for short hairpin
RNA (shRNA). The shRNA sequences targeting DOCK180 and firefly lucif-
erase were 5-GTTTCTTCAGGACACGTTG-3 and 5-GATTATGTCCGGT-
TATGTA-3, respectively. For RNA interference (RNAi), rescue experiments,
an shRNA-resistant construct was created by introducing seven silent point
mutations in the target sequences (TTCCTGCAGGATACCTTAGACGCT),
generating pCA-EGFP-DOCK180R, -DHR1R, and -DHR1R-RLC. For retroviral
infection, a Moloney murine leukemia virus-based retroviral vector plasmid,
pMSCVpac-EGFP-SNX5, was constructed.
Antibodies
The polyclonal antibodies against DOCK180 were developed in our labora-
tory and described previously (Hasegawa et al., 1996). Antibodies used in this
study were purchased as follows: Mouse anti-FLAG antibody (Sigma-Al-
drich, St. Louis, MO), mouse anti-green fluorescent protein (GFP) antibody
(Clontech, Mountain View, CA), mouse anti-pan extracellular signal-regu-
lated kinase (ERK) antibody (BD Biosciences, San Jose, CA), mouse anti-SNX1
antibody (BD Biosciences), goat anti-SNX5 antibody (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), rabbit anti-SOS2 antibody (Santa Cruz Biotechnology),
sheep anti-TGN46 antibody (Serotec, Oxford, United Kingdom), mouse anti-
Golgin97 antibody (Invitrogen), mouse monoclonal anti-CD8 antibody
(Alexis Biochemicals, Lausen, Switzerland), mouse Alexa Fluor488-conju-
gated anti-CD8 antibody (Serotec), Alexa Fluor488-conjugated mouse mono-
clonal anti-CD8 antibody (Serotec), mouse anti-early endosomal antigen
(EEA)1 antibody (BD Biosciences), mouse anti-tubulin antibody (Calbiochem,
San Diego, CA), anti-goat IRDye 800CW, anti-mouse IRDye 800CW, and
anti-rabbit IRDye 680 (LI-COR Biosciences, Lincoln, NE), goat Alexa Flu-
or488-conjugated anti-mouse immunoglobulin G (IgG), and donkey Alexa
Fluor568-conjugated anti-goat IgG (Invitrogen).
Cell Culture and Transfection
HeLaM cells stably expressing CD8-CI-MPR were provided by Dr. Matthew
N. J. Seaman (University of Cambridge, Cambridge, United Kingdom) and
cultured in DMEM containing 500 g/ml G418 and 10% fetal bovine serum as
described previously (Seaman, 2004). HeLa and 293T cells were grown at 37°C
in DME supplemented with 1 g/ml penicillin-streptomycin and 10% fetal
bovine serum. 293F cells were maintained at 37°C in FreeStyle 293 expression
medium (Invitrogen) and transfected with various plasmids by using 293Fec-
tin reagent (Invitrogen) according to the manufacturer’s instructions. To
establish the HeLa cells stably expressing GFP-SNX5, the murine ecotropic
retrovirus receptor (EcoVR) was first introduced by using the virus produced
from BOSC23 cells by transfecting with pCX4hyg-EcoVR, the packaging
plasmid pGP, and the envelope plasmid pVSV-G (Akagi et al., 2003; Terai and
Matsuda, 2006). After selection by hygromycin, EcoVR-expressing HeLa cells
were infected with pMSCVpac-EGFP-SNX5, followed by puromycin selection.
Identification of Interacting Proteins
293T cells were transfected with pCAP-FLAG-DHR1, and binding proteins
were analyzed by direct nanoflow liquid chromatography (DNLC)/tandem
mass spectrometry (MS/MS) as described previously (Natsume et al., 2002).
Briefly, the samples were processed under a stable flow using DNLC. This
consists of the following components: a high-pressure syringe pump (KYA
Technologies, Tokyo, Japan), a gradient device consisting of 10-channel sol-
vent reservoirs (Valco, Houston, TX), a high-pressure pump mixing module
(Hewlett Packard, Palo Alto, CA), and an electrospray ionization column
packed with 1-m reversed-phase beads (Kanto Chemical, Tokyo, Japan).
Samples processed through DNLC were injected at flow rates of 25–500
nl/min, and tandem mass spectra were obtained.
Pull-Down Assay and Immunoprecipitation
Twenty-four hours after transfection, 293F cells were washed with Tris-
buffered saline (TBS) and lysed with ice-cold lysis buffer (10 mM Tris-HCl, pH
7.5, 5 mM EDTA, 1% Triton X-100, 10 mM NaF, 1 mM Na3VO4, 2 mM
phenylmethylsulfonyl fluoride, and 10 g/ml aprotinin). The cleared lysates
were incubated with glutathione-Sepharose beads (GE Healthcare, Little
Chalfont, Buckinghamshire, United Kingdom) at 4°C for 30 min. After wash-
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ing with ice-cold lysis buffer, proteins bound to beads were separated by
SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to a polyvi-
nylidene difluoride membrane, followed by detection with antibodies de-
scribed above. The bound antibodies were detected by an enhanced chemi-
luminescence detection system (GE Healthcare), and binding was quantified
with the aid of an LAS-1000 image analyzer (Fuji Film, Tokyo, Japan). In some
experiments, LI-COR Odyssey infrared imaging system scanner (LI-COR
Biosciences) was used. For immunoprecipitation, GFP-SNX5–expressing
HeLa cells were lysed in lysis buffer and incubated with anti-GFP antibody at
4°C for 60 min, followed by incubation with protein A/G-Sepharose beads
(GE Healthcare). The precipitates were processed similarly as described
above.
Lipid Binding Assay
293T cells were transfected with various plasmids by 293Fectin (Invitrogen).
Forty-eight hours later, cells were collected and lysed in lipid-binding buffer
(50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 1 mM EDTA, 0.1% Triton X-100, 5
g/ml aprotinin, and 1 mM PMSF) on ice. The amount of GFP-tagged
proteins was quantified by SDS-PAGE and Western blotting with anti-GFP
antibody (Clontech), and the same amount of proteins was diluted by the
lipid-binding buffer and incubated to beads conjugated by Di-C6 or Di-C6 PIP3
(Echelon, San Diego, CA). After 6–8 h, the beads were washed twice with
lipid washing buffer, 50 mM HEPES, pH 7.4, 150 mM NaCl, 0.25% NP-40, and
separated by SDS-PAGE. The proteins bound to the beads as well as normal-
ized total cell lysates were visualized by Western blotting with anti-GFP
antibody. Similarly, 293F cells were transfected with several combinations of
pCA-EGFP-DOCK180 and pCA-FLAG-SNX5, and they were further analyzed
using beads coated with various lipids.
In Vitro Binding Assay
Recombinant proteins fused with glutathione-S-transferase (GST) were ex-
pressed in Escherichia coli JM109 transformed by pGEX-6P3-SNX5 and pGEX-
4T3-DHR1 and purified by the use of Aktaprime (GE Healthcare). To obtain
SNX5, GST-SNX5 was treated with Prescission protease (GE Healthcare). The
quality and quantity of proteins were confirmed by SDS-PAGE and Coomas-
sie Brilliant Blue (CBB) staining. Purified SNX5 and GST-DHR1 or GST
proteins were incubated with glutathione-Sepharose beads at room temper-
ature for 20 min. After washing with PBS twice, the precipitates were sub-
jected to SDS-PAGE, and bound SNX5 protein was detected by Western
blotting using anti-SNX5 antibody.
RNA Interference
Small interfering RNA (siRNA) oligonucleotides against human DOCK180
and Rac1 were purchased from Dharmacon RNA Technologies (Lafayette,
CO). The sequences were as follows. DOCK1-1: sense, 5-GUACCGAG-
GUUACACGUUAUU-3; DOCK1-2: sense, 5-GAAAGUCGAUGGUGGU-
GAAUU-3; DOCK1-3: sense, 5-UAAAUGAGCAGCUGUACAAUU-3;
DOCK1-4: sense, 5-GGCCCAAGCCUGACUAUUU-UU-3; Rac1-1: sense, 5-
UAAGGAGAUUGGUGCUGUAUU-3; Rac1-2: sense, 5-AGACGGAGCUGUAG-
GUAAAUU-3; Rac1-3: sense, 5-UAAAGACACGAUCGA-GAAAUU-3; and
Rac1-4: sense, 5-CGGCACCACUGUCCCAACAUU-3.
siRNA against SNX5 (5-CGCUCAGUGAGAGAGACAAAGUCAA-3) and
SNX1 (5-ACUCUAGUCAACCAUAGGA-3) were from Gene Design
(Osaka, Japan; Gullapalli et al., 2004). SOS2 oligonucleotide (sense, 5-GCCU-
UUGCUAGAAAAUGCAGAAACU-3; iGENE Therapeutics, Tsukuba, Ja-
pan) was used as a negative control. Cells were seeded at a density of 1  104
cells per well on a noncoated 24-well plate (Nalge Nunc International, Roch-
ester, NY) the day before transfection, and they were transfected with siRNA
oligonucleotides using RNAi MAX (Invitrogen) according to the manufactur-
er’s protocol. Forty-eight hours after transfection, the cells were processed for
immunostaining for CD8-CI-MPR, TGN46, and EEA1, or they were lysed in
lysis buffer and subjected to SDS-PAGE and Western blotting to confirm
protein depletion.
Immunostaining and Immunofluorescence Microscopy
HeLa and CD8-CI-MPR–expressing HeLaM cells were plated on collagen-
coated 35-mm glass-bottomed dishes (Iwaki Glass, Tokyo, Japan) and treated
with siRNA as described previously. Forty-eight hours after transfection, cells
were fixed in 4% paraformaldehyde/phosphate-buffered saline (PBS) for 10
min at room temperature and permeabilized with 0.1% Triton X-100/PBS for
10 min. After incubation in 10% fetal bovine serum/PBS, cells were incubated
with primary antibodies for 1 h, followed by incubation with fluorescent-
conjugated secondary antibodies for 1 h at room temperature. To release
cytoplasmic proteins, 48 h after transfection, HeLa cells plated on polyethyl-
eneimine-coated 35-mm glass-bottomed dish were treated with 0.001% sapo-
nin at room temperature for 5 min before fixation. Fluorescent images were
obtained by inverted epifluorescence microscopy by using an IX71 or IX81
microscope (Olympus, Tokyo, Japan) and processed and analyzed by Meta-
Morph software (Molecular Devices, Sunnyvale, CA). In some experiments,
cells were imaged with an FV-500 or -1000 confocal microscope equipped
with an Argon and HeNe laser (Olympus).
Anti-CD8 Antibody Uptake Experiment
An anti-CD8 antibody uptake experiment was performed as described pre-
viously (Carlton et al., 2005). Briefly, HeLaM cells were plated on collagen-
coated 35-mm glass-bottomed dishes and transfected with various siRNA
oligonucleotides at a concentration of 1 nM. After 48 h, cells were washed and
incubated with DHB buffer (DMEM containing 25 mM HEPES and 0.2%
bovine serum albumin) at 4°C for 15 min and labeled with 10 ng/l anti-CD8
antibody in DHB buffer for 1 h at 4°C. After washing at 4°C with DHB buffer,
cells were incubated with prewarmed DMEM containing 10% fetal bovine
serum at 37°C to allow internalization of CD8-CI-MPR from the cell surface.
Thirty minutes after internalization, cells were washed in ice-cold PBS and
fixed and stained with Alexa Fluor488-conjugated secondary antibody. TGN
was visualized using anti TGN46 antibody followed by Alexa Fluor568-
conjugated secondary antibody. To express the CD8-CI-MPR internalized
from cell surface and trafficked to TGN, two images of TGN46 and intracel-
lular CD8-CI-MPR were obtained using epifluorescence microscopy. After
subtraction of background intensity, binary images of TGN46 and CD8 were
obtained using arbitrary threshold. TGN46 image was overlaid on the CD8
image, yielding the area where CD8-CI-MPR colocalizes with TGN46. The
nuclear area was excluded from analysis in all the images because of non-
specific staining of the secondary antibodies in the nuclei. The obtained CD8
area within TGN46 was divided by the total CD8-CI-MPR area within the
cells, and then used as the index of CD8-CI-MPR transported to TGN. Whole
CD8 area within cells was divided by cell area and used as the CD8-CI-MPR
internalized from cell surface. Alternatively, cells were incubated with mouse
Alexa Fluor488-conjugated anti-CD8 antibody to follow CD8-CI-MPR, and
anti-Golgin97 antibody was used to mark the Golgi apparatus. Obtained
images were processed similarly described above; except for that whole cell
area was included into analysis to evaluate total volume of internalized
CD8-CI-MPR.
Microinjection
Microinjections were performed under an inverted microscope (Carl Zeiss,
Jena, Germany) with a micromanipulator 5171 (Eppendorf, Hamburg, Ger-
many) by using an automated FemtoJet (Eppendorf) and glass microcapillar-
ies (Femtotips; Eppendorf). CD8-CI-MPR–expressing HeLaM cells were
plated on collagen-coated 35-mm glass-bottomed dishes at a density of 1 
105 cells per dish, and 100–200 ng/l plasmids were microinjected. The
injection parameters were kept as follows: Pi, 30 hPa; Ti, 0.1 s; and Pc, 30 hPa.
Cells were incubated for more than 48 h, followed by immunostaining using
anti-CD8 antibody as described above.
RESULTS
SNX5 Is a Novel Binding Partner of the DHR1 Domain of
DOCK180
To understand the function of the DHR1 domain, we searched
for cellular proteins that physically associate with DHR1 in
mammalian cells. For this purpose, FLAG-DHR1 (amino acids
422-664) was expressed in 293T cells and immunoprecipitated
from cell lysates with anti-FLAG antibody. The immunopre-
cipitates were eluted with FLAG peptides, digested with Lys-C
endopeptidase, and analyzed using a highly sensitive direct
nanoflow LC-MS/MS as described previously (Natsume et al.,
2002). A database search identified nine proteins that interact
with DHR1, as shown in Table 1. Among the listed proteins,
Table 1. Detection of SNXs as binding partner of DOCK180
Protein name Resultsa
Sorting nexin1 2/2
Sorting nexin2 2/2
Sorting nexin5 2/2
Sorting nexin6 2/2
Proteasome subunit,  type, 1; isoform unknown 2/2
Prostaglandin E synthase 2; isoform unknown 2/2
Cyclophilin family 1/2
Proteasome subunit,  type, 7 family 1/2
Proteasome 26S subunit, non-ATPase, 2 1/2
a Positive results/total experiments.
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SNX1, 2, 5, and 6 were found to associate with DHR1 repeat-
edly, validating further analyses.
To confirm the binding of DHR1 to SNXs, 293F cells were
transfected with plasmids for GST-tagged DHR1 and FLAG-
tagged SNXs (Figure 1A). GST-DHR1 collected on glutathi-
one-Sepharose was found to associate with SNX5. After a
long exposure of the filter, we could detect the interaction of
DHR1 to other SNXs (data not shown). Because recent stud-
ies have shown that SNXs form homo- and hetero-oligomers
(Parks et al., 2001; Liu et al., 2006), we examined whether
SNX5 was associated with other SNXs in our experimental
condition (Supplemental Figure S1A). We found that SNX5
associated with SNX1 and SNX2, and also with SNX6, albeit
to a lesser extent. These data suggest that DHR1 directly
binds to SNX5 and indirectly to SNX1, 2, and 6 via SNX5.
SNX5 Specifically Interacts with DOCK180
DOCK180 belongs to the DOCK180 superfamily, which con-
tains at least 11 human DOCK180 homologues and several
homologous members in other species. The binding of SNX5
to the DHR1 domain of other DOCK180 members was ex-
amined in 293F cells (Supplemental Figure S1B). Among the
tested DHR1 domains of DOCK180 family proteins—
DOCK2, DOCK3, DOCK4, DOCK6, and DOCK9—only the
DHR1 domain of DOCK180 showed binding to SNX5 to a
detectable level. To examine whether the full-length
DOCK180 also interacts with SNX5, GST-tagged SNX5 and
FLAG-tagged DOCK180 or DHR1 were expressed in 293F
cells, followed by pull-down analysis with glutathione-
Sepharose. As shown in Figure 1B, the full-length DOCK180
bound to SNX5 as did DHR1.
We next examined the interaction between DOCK180 and
SNX5 at the physiological expression level. Before this anal-
ysis, we quantified the molecule numbers of the endogenous
DOCK180, SNX1, and SNX5 in HeLa cells essentially as
described previously (Aoki et al., 2007) (Table 2 and Supple-
mental Figure S2). We found that DOCK180 is 10 times
fewer than SNXs. Because the SNX5 antibody used in this
study could not immuno-precipitate SNX5 efficiently, we
failed to detect DOCK180 in the immune complex (data not
shown). To overcome this, we established HeLa cells stably
expressing GFP-SNX5. In these GFP-SNX5–expressing cells,
the expression level of the endogenous SNX5 protein was
decreased (Figure 1C). When the amount of endogenous and
exogenous SNX5s was quantified in these cells, the sum of
endogenous and exogenous SNX5s in the GFP-SNX5–ex-
pressing cells was 1.5 times as much as the endogenous
SNX5 in the parental cells. Using these cells, we could show
the coprecipitation of endogenous DOCK180 with the GFP-
SNX5 protein (Figure 1D), indicating that the expression
levels of endogenous SNX5 and DOCK180 are sufficient to
form the SNX5–DOCK180 complex.
To demonstrate direct interaction of DHR1 and SNX5, we
prepared GST-tagged DHR1 and SNX5 expressed in E. coli.
GST-SNX5 was further cleaved by a protease to remove
GST-tag. With these recombinant proteins, we found that
SNX5 was coprecipitated with GST-DHR1, but not with GST
alone, demonstrating the direct interaction of DHR1 with
SNX5 (Figure 1E).
DOCK180 Localizes to Endosomes with SNX5
Previously, it has been reported that the localizations of
SNX5 and DOCK180 are early endosomes and cytoplasm,
respectively (Hasegawa et al., 1996; Teasdale et al., 2001). To
examine SNX5 and DOCK180 interaction in the cell, SNX5
and DOCK180 with fluorescent proteins were expressed in
HeLa cells, and observed with confocal microscopy (Figure
2A). As reported previously, GFP-DOCK180, as well as GFP
and red fluorescent protein (RFP), is localized in the cyto-
plasm, whereas GFP- and RFP-SNX5 localized to the vesicles
in the fixed cells. Because we anticipate that abundant
DOCK180 in the cytoplasm perturbs observation of DOCK180 at
the vesicles, cells expressing RFP-SNX5 and GFP-DOCK180
were treated with 0.001% saponin before fixation to release
cytoplasmic proteins from the cells (Figure 2B). Although
SNX5 localized mainly to the vesicles, DOCK180 localized
both to cytoplasm and vesicles, which are merged to SNX5,
suggesting that a small fraction of DOCK180 binds to SNX5.
The First Helix of the SNX5 Bin/Amphiphysin/Rvs (BAR)
Domain Is Necessary for Binding to DHR1
SNX5 contains the N-terminal PX domain (amino acids 64–
168) and the C-terminal coiled-coil region encoding the BAR
domain (206-397) (Figure 3A) (Merino-Trigo et al., 2004).
SNXs are subgrouped into seven classes based on their
amino acid sequence similarity of PX domain (Worby and
Dixon, 2002). The SNX5, together with SNX1, SNX2, and
SNX6, is classified into the same group. X-ray crystallogra-
phy has revealed that the BAR domain conforms to a coiled-
coil structure consisting of three  helices, 1–3 (Peter et al.,
2004). To identify the helix responsible for the DHR1 bind-
ing, we first attempted to express each helix alone, but they
were all insoluble or unstable in tissue culture cells. Thus, in
the following experiment we used C-terminal–truncated
mutants as schematically shown in Figure 3A. Comparable
expression levels of these FLAG-tagged SNX5 mutants were
confirmed in 293F cells (Figure 3B). Next, we examined the
binding of GST-DHR1 to these truncated mutants. As shown
in Figure 3C, truncated mutants containing the first and
second helices of the BAR domain associated with DHR1 to
a similar extent as the full-length SNX5. When all of the BAR
domains was deleted from SNX5 in the PX mutant, SNX5
did not associate with DHR1. Although the insolubility of
the BAR domain prevented us from directly evidencing it,
the data strongly suggested that the first helix of the BAR
domain bound to DHR1. Alternatively, our observation
might suggest that the PX domain played an essential role in
DHR1 binding, and the first helix of the BAR domain might
contribute to this simply by stabilizing the conformation of
the PX domain. Regardless, we concluded that the first helix
of the BAR domain was necessary for association with
DHR1.
DOCK180 Deficiency Alters the Distribution of CI-MPR
SNX1 is a component of the retromer complex, which func-
tions in the retrieval process of CI-MPR from early endo-
some to TGN (Carlton et al., 2004). The RNAi loss-of-func-
tion screen of SNXs has identified SNX5 and SNX6 as
potential components of the retromer (Wassmer et al., 2007).
These observations prompted us to examine whether
DOCK180 is involved in this retrograde transport of CI-MPR
through the binding to SNX5. Previous studies have shown
that knockdowns of SNX1 and SNX5 induced redistribution
of endogenous and CD8-tagged CI-MPR from TGN to en-
dosomes. When this CD8-CI-MPR-reporter protein, consist-
ing of the extracellular domain of CD8 and the cytoplasmic
domain of bovine CI-MPR, is expressed in HeLa cells, it
cycles between endosomes and TGN (Seaman, 2004). During
this cycle, the retromer regulates the retrieval of CD8-CI-
MPR from endosome to TGN. We examined whether the
DOCK180 knockdown altered the steady-state distribution
of CD8-CI-MPR, as did that of SNX5. HeLaM cells, which
constitutively express CD8-CI-MPR, were transfected with
siRNA duplexes against DOCK180, SNX5, and SOS2 (Figure
S. Hara et al.
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Figure 1. DOCK180 binds to SNX5. (A) 293F cells were transfected with various combinations of plasmids for proteins indicated at the
bottom. After 24 h, cells were lysed and supernatants were incubated with glutathione-Sepharose. After the beads were washed with ice-cold
lysis buffer, bound proteins (denoted as pull-down) as well as total lysate were separated by SDS-PAGE and detected by Western blotting
with antibodies against FLAG and GST indicated to the left. The corresponding bands to ERK2, SNXs, GST, and GST-DHR1 are denoted to
the right. Three independent experiments demonstrated similar results. (B) 293F cells were cotransfected with various combinations of
plasmids encoding proteins as indicated at the bottom. Cells were processed and analyzed as described for A. The corresponding bands to
DOCK180, DHR1, mSos1, GST-SNX5, and GST are denoted to the right. (C) Establishment of GFP-SNX5 expressing HeLa cells. Lysates from
the parental (left lane) and GFP-SNX5 expressing (right lane) HeLa cells were subjected to SDS-PAGE and Western blotting using indicated
antibodies. The corresponding bands to endogenous or GFP-tagged SNX5 and tubulin are indicated to the right. The intensities of
endogenous and exogenous SNX5 bands in GFP-SNX5–expressing cells were divided by that of endogenous SNX5 in the parental cells and
shown in the graph. Black and gray bars represent endogenous and GFP-tagged SNX5, respectively. (D) Binding of endogenous DOCK180
to GFP-SNX5. GFP-SNX5 expressing HeLa cells were lysed and supernatants were incubated with anti-GFP antibody. Proteins were collected
by protein A/G-Sepharose beads, separated by SDS-PAGE, and detected with indicated antibodies. Bands corresponding to DOCK180 and
GFP-tagged SNX5 are indicated to the right. IP, immunoprecipitate. (E) In vitro binding of GST-DHR1 and SNX5. GST-DHR1, GST, and SNX5
protein were expressed in E. coli and purified. GST-SNX5 was cleaved with a protease to obtain SNX5 without GST. The proteins were
separated by SDS-PAGE, stained with CBB. The corresponding bands to GST-DHR1, GST, and SNX5 are indicated to the right (left). SNX5
and GST-DHR1 or GST proteins were incubated with glutathione-Sepharose beads at room temperature for 20 min and separated by
SDS-PAGE. The bound SNX5 protein was detected by Western blotting using anti-SNX5 antibody (right).
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4A). The SOS2 siRNA was used as a control. The oligonu-
cleotide treatment at concentrations of both 1 and 5 nM
specifically reduced the expression of targeted proteins 48 h
after transfection, to 10–20% of that without the treatment
(Figure 4B). In parallel, these cells were immunostained with
anti-CD8 antibody (Figure 4C). In cells without or with
control siRNA treatment, most of the CD8-CI-MPR re-
mained in the perinuclear region, as reported for the endog-
enous CI-MPR. This perinuclear staining colocalized with
Figure 2. SNX5 and DOCK180 localizes to the vesicles. (A) HeLa
cells were transfected with plasmids encoding proteins indicated
above. Forty-eight hours later, cells were fixed and imaged by
confocal microscopy. Enlarged images from red squares in the top
panels are shown at the bottom. Bar, 20 m. (B) HeLa cells were
cotransfected with plasmids for RFP-SNX5 and GFP-DOCK180.
Forty-eight hours later, cells were treated with 0.001% saponin for 5
min at room temperature, before fixation. Images were obtained by
confocal microscopy. Enlarged images from squares in the top
panels are shown at the bottom. Arrowheads indicate colocalization
of SNX5 and DOCK180. Bar, 20 m.
Figure 3. The first helix of the BAR domain is necessary for inter-
action with the DHR1 domain. (A) Schematic representation of
SNX5 mutants. Numbers at the top of each bar indicate the amino
acid numbers of human SNX5. The domains corresponding to PX,
BAR, and helices 1–3 are shown in the full (that is, the wild type) at
the bottom. The BAR domain consists of three helices, 1–3. (B) 293F
cells were transfected to express proteins indicated at the bottom.
Twenty-four hours later, cells were collected and directly lysed in
SDS-sample buffer. Proteins were separated by SDS-PAGE and
examined by Western blotting with anti-FLAG antibody. The cor-
responding bands to full-length and mutants of SNX5 are denoted
to the right. (C) 293F cells transiently expressing the proteins indi-
cated at the bottom were analyzed as in Figure 1A. The bands
corresponding to the full-length and mutants of SNX5, GST, and
GST-DHR1 are denoted to the right. Three independent experi-
ments demonstrated similar results.
Table 2. Number of DOCK180, SNX1, and SNX5 in HeLa cells
No. (/cell)
DOCK180 3.9  105
SNX1 4.3  106
SNX5 3.0  106
HeLa cells were transfected with plasmids for GFP-DOCK180,
-SNX1, and -SNX5 and lysed in lysis buffer. Proteins were separated
by SDS-PAGE and detected by Western blotting with anti-GFP
antibody. GST-5myc-FLAG-3HA-YFP protein was expressed E. coli
and used as a standard as described previously (Aoki et al., 2007).
The same proteins were examined by Western blotting with anti-
bodies against DOCK180, SNX1, and SNX5 to calculate the numbers
of endogenous proteins. The representative images were shown in
Supplemental Figure S2. Results obtained from three independent
experiments.
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Figure 4. Suppression of DOCK180 alters steady-state distribution of the CI-MPR. (A) CD8-CI-MPR–expressing HeLaM cells were treated
for 48 h with SOS2-, SNX5-, or DOCK180-targeted siRNA oligonucleotides (indicated at the top), in a concentration of 1 or 5 nM, and
examined for protein depletion by SDS-PAGE and Western blotting with antibodies against SOS2, SNX5, DOCK180, and pan-ERK as
indicated to the right. (B) Suppression of SOS2, SNX5, and DOCK180 proteins was quantified from Western blotting in A. The intensities of
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that of a TGN marker, TGN46 (Figure 4D). In contrast, the
knockdown of SNX5 or that of DOCK180 dispersed the
CD8-CI-MPR at TGN, resulting in the formation of a periph-
eral punctate structure (Figure 4C, bottom). To quantify the
degree of CD8-CI-MPR redistribution caused by DOCK180
or SNX5 deficiency, cells were divided into two typical
phenotypes according to the CD8-CI-MPR distribution (Sup-
plemental Figure S3): 1) the TGN pattern and 2) the dis-
persed pattern showing peripheral punctate localization. In
DOCK180-deficient cells, 36.8  4.2% of cells showed a
dispersed pattern of CD8-CI-MPR, which was less than that
observed in SNX5 knockdown cells (Figure 4E) but signifi-
cantly higher than that in the control cells (p  0.05). Be-
cause this morphological classification is liable to fluctua-
tion, we performed a blind test in which three pathologists
classified the stained cells into either TGN or the dispersed
pattern without any information on the transfected siRNA
(Supplemental Figure S4). Although the absolute numbers
varied among the three examiners, all examiners reached the
same conclusion: the dispersed pattern of CI-MPR occurs
most frequently in SNX1-depleted cells, and, to a lesser
extent, in DOCK180-depleted cells. To examine the subcel-
lular localization of the dispersed CI-MPR in DOCK180-
deficient cells, cells were stained with an early endosomal
marker, EEA1 (Figure 4F). In control cells, CD8-CI-MPR was
mainly localized to TGN. In contrast, in cells treated with
siRNA oligonucleotides against SNX5 and DOCK180, the
peripheral CD8-CI-MPR-labeled structures exhibited partial
colocalization with EEA1. These data strongly supported
our view that DOCK180 regulates the retrograde transport
of CI-MPR similarly to SNX5.
Internalization and Trafficking of CD8-CI-MPR Are
Disturbed in DOCK180-deficient Cells
To examine whether the alteration in the steady-state distri-
bution of CD8-CI-MPR resulted from a perturbation in the
kinetics of early endosome-to-TGN transport, we examined
the uptake of anti-CD8 antibodies. HeLaM cells were treated
with siRNAs as described above, and they were incubated
with anti-CD8 antibody at 4°C to label CD8-CI-MPR ex-
pressed on the plasma membrane, followed by warming to
37°C for 30 min to allow its internalization from the cell
surface. The CD8-CI-MPR was transported through the
early endosome, and the bulk reached TGN by the time of
observation. After 30-min incubation, most of the CD8-CI-
MPR was found to be localized to TGN in control cells,
whereas significantly less CD8-CI-MPR was observed
within TGN and instead distributed in peripheral vesicular
structure in the SNX5- or DOCK180-deficient cells (Figure
5A). Because retromer regulates cargo protein sorting from
endosome to TGN, the retromer function can be monitored
by the level of CD8-CI-MPR that has been retrieved to TGN
(Carlton et al., 2005). For this, we measured the total area of
CD8-CI-MPR showing the colocalization with TGN46 as
described in Materials and Methods. Although the total area of
internalized CD8-CI-MPR was at similar level in control
cells and SNX5- or DOCK180-depleted cells (Figure 5B, left
column), the CD8-CI-MPR reached to TGN was less in both
SNX5- or DOCK180-depleted cells (Figure 5B, right column).
Furthermore, a previous study has shown that SNX5 knock-
down induces TGN fragmentation (Wassmer et al., 2007).
We confirmed this observation (Figure 5C) and found that
DOCK180 knockdown induced similar TGN fragmentation,
further supporting our view that DOCK180 cooperates with
SNX5. Instead of TGN46, another marker for the TGN, Gol-
gin97, was used to show that the distribution of Golgin97
was not affected by siRNA treatment against SNX5 and
DOCK180 (Figure 5D). We quantified the CD8-CI-MPR traf-
ficking inhibition under this condition, to find that the trans-
port of CD8-CI-MPR to TGN marked by Golgin97 was af-
fected more severely than that to TGN marked by TGN46
(Figure 5E).
Depletion of Rac1 Did Not Affect CI-MPR Transport
An established function of DOCK180 is to activate Rac1,
which regulates actin organization (Kiyokawa et al., 1998a).
A recent study has demonstrated the retromer-component
proteins VPS26 and VPS35 localized to ruffles at the plasma
membrane, which are rich in polymerized actin (Kerr et al.,
2005). To address the question of whether Rac1 is required
for CI-MPR trafficking, HeLaM cells were treated with
siRNA duplexes against Rac1 for 48 h to reduce protein
expression to an undetectable level (Figure 6A). In these
Rac-deficient cells, the steady-state distribution of CD8-CI-
MPR examined as in Figure 4E was similar to that of the
control cells, negating the involvement of Rac1 in CI-MPR
localization (Figure 6B).
RLC Mutation in DHR1 Ablates the DOCK180 Binding to
SNX5 and Phosphoinositide
Recently, a 27-base pair deletion in the DHR1 domain of
mouse DOCK5 was discovered in a RLC mutant, a heredi-
tary cataract in mice (Omi et al., 2008). We introduced this
deletion, corresponding to amino acids 488–496, into DHR1
of human DOCK180, and we examined its binding to SNX5.
As shown in Figure 7A, RLC deletion of DHR1 diminished
the binding to SNX5. This observation indicates that SNX5
binds to DOCK180 through DHR1 and suggests that SNX5
binding is an essential physiological function of DOCK180.
Cote et al. (2005) have found that DHR1 binds to PIP3 and
PI(3,5)P2, through amino acid residues 422-619. Because
RLC mutation is located in the minimal lipid-binding site,
we next examined the effect of RLC mutation on the lipid
Figure 4 (cont). SOS2, SNX5, and DOCK180 bands were divided
by those of pan-ERK from the same lanes to obtain the normalized
intensities. Relative protein expression was calculated by normal
intensity from the siRNA-treated sample divided by that from
siRNA nontreated sample. The treated siRNA duplexes are indi-
cated at the bottom of the graph. Black, gray, and white bars
indicate the relative amounts of SOS2, SNX5, and DOCK180, respec-
tively. (C) In a parallel experiment in A, siRNA-treated cells were
fixed in 4% paraformaldehyde and immunostained with anti-CD8
antibody and Alexa Fluor 488-conjugated secondary antibody. Cell
images were acquired with confocal microscopy. Representative
image of cells treated with 1 nM siRNA oligonucleotides are shown.
Enlarged images from red squares in the top panels are shown at the
bottom. Bar, 20 m. (D) CD8-CI-MPR–expressing HeLaM cells were
fixed and stained with anti-CD8 and anti-TGN46 antibodies, fol-
lowed by Alexa-conjugated secondary antibodies. Cell images were
obtained with confocal microscopy. Enlarged images in the insets
are shown at the bottom. Bar, 20 m. (E) Quantitative analysis of
percentage of cells with CI-MPR dispersed in siRNA-treated cells.
Results were obtained from cells treated with 1 nM and 5 nM of
siRNA oligonucleotides as two independent experiments. Repre-
sentative images for quantitative analysis are shown in Supplemen-
tal Figure S3. More than 50 cells were counted in all experiments,
and mean  SD percentage of cells with dispersed CI-MPR is
shown. Asterisks indicate the significance of t test analysis: *p 0.05
(vs. control siRNA). (F) CD8-CI-MPR-expressing HeLaM cells were
fixed and stained with anti-CD8 (left) and EEA1 (middle) antibod-
ies. Cell images were obtained by confocal microscopy. Treated
siRNA duplexes are denoted to the left. Bar, 10 m. Enlarged
images from green and red squares in the top panels are shown at
the bottom. Arrowheads indicate vesicles where CD8-CI-MPR and
EEA1 are colocalized.
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recognition of DOCK180. As shown in Figure 7B, the wild-
type DOCK180, but not the RLC mutant, bound to PIP3, as
described previously (Kobayashi et al., 2001; Cote et al.,
2005). To investigate whether SNX5 competes with PIP3 for
the binding to DOCK180, DOCK180 in the presence or ab-
sence of SNX5 were incubated with the beads coated with
PIP3 or PI(4,5)P2 (Figure 7C). The amounts of DOCK180
bound to the PIP3 beads were not changed in the presence or
absence of SNX5, as shown in the first and second rows.
Furthermore, SNX5 was found to be coprecipitated with
Figure 5. Kinetics of CD8-CI-MPR is altered
in DOCK180-suppressed cells. (A) CD8-CI-
MPR–expressing HeLaM cells were treated
with 1 nM SOS2-, SNX5-, or DOCK180-tar-
geted siRNA oligonucleotides. Forty-eight
hours later, cells were incubated with anti-
CD8 antibody at 4°C for 1 h. After labeling,
cells were warmed up to 37°C, incubated for
30 min, and fixed (denoted as 30 min to
the left). Cells were then stained with Alexa
Fluor488-conjugated secondary antibody, and
images were obtained with confocal micros-
copy. Representative images of CD8-CI-MPR–
expressing HeLaM cells treated with siRNA
oligonucleotides indicated at the top were
shown. For negative control for staining, cells
without siRNA treatment were processed sim-
ilarly but without anti-CD8 antibody (left col-
umn). Enlarged images from red squares in
the top panels are shown at the bottom. Bar,
20 m. (B) Quantitative analysis of CD8-CI-
MPR internalized from cell surface (left) and
trafficked to TGN (right panel) as described in
Materials and Methods. Data are shown as a
relative amount of CD8-CI-MPR compared
with no-siRNA oligonucleotides treated cells
and expressed as mean  deviation form two
independent experiments. More than 30 cells
were analyzed in each experiment. (C) In the
parallel experiment in A, TGN was visualized
with epifluorescence microscopy, and repre-
sentative images of cells treated with siRNA
oligonucleotides indicated at the top are
shown. Enlarged images from red squares in
the top panels are shown at the bottom. Bar, 20
m. (D) siRNA-treated CD8-CI-MPR–ex-
pressing HeLaM cells were immunostained with
anti-Golgin97 antibody and Alexa Fluor488-conju-
gated secondary antibody. Images were obtained
and shown as in C. Bar, 20 m. (E) Quantitative
analysis of anti-CD8 uptake assay using mouse
Alexa Fluor488-conjugated anti-CD8 and anti-Gol-
gin97 antibodies and as described in Materials and
Methods. Data from two independent experiments
are shown as in (B). In each experiment, 15–27 cells
were analyzed. Bar represents mean  deviation.
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PIP3-coated beads only in the presence of DOCK180. Al-
though we could not perform similar experiments with
PI(3,5)P2 due to a technical problem, these data suggest that
DOCK180 bridges the SNX5-bearing protein complexes to
the membranes rich in PIP3 or PI(3,5)P2.
DHR1 Is Sufficient for CI-MPR Transport
Last, we challenged the question of whether or not DHR1 is
sufficient for the role that DOCK180 plays in CD8-CI-MPR
transport. We prepared pSuper-DOCK180, a vector-based
shRNA targeting DOCK180, as well as pCA-EGFP-
DOCK180R, pCA-EGFP-DHR1R, and pCA-EGFP-DHR1R-
RLC, expression vectors for the DOCK180 mRNAs that are
resistant to the aforementioned shRNA. Expression levels of
these proteins were examined in 293F cells by Western blot-
ting (Supplemental Figure S5). To ensure the coexpression,
we microinjected these plasmids into HeLaM cells and ex-
amined their effects on CD8-CI-MPR distribution. As ex-
pected, shRNA for DOCK180 induced the dispersed CD8-
CI-MPR pattern, and this effect of shRNA was ablated by the
coexpression of shRNA-resistant DOCK180 (Figure 7D). A
similar experiment was conducted with shRNA-resistant
DHR1 of DOCK180 (Figure 7E). We found that reexpression
of DHR1R suppressed the shRNA-induced dispersion of
CD8-CI-MPR as efficiently as that of the full-length
DOCK180. However, expression of shRNA-resistant RLC
mutant of DHR1 could not restore the steady-state distribu-
tion of CI-MPR in DOCK180-suppressed cells (Figure 7E).
Thus, we concluded that DHR1 of DOCK180 is sufficient to
regulate the retrograde transport of CI-MPR.
DISCUSSION
In this study, we have identified SNX5 as a novel binding
partner of DOCK180 by nano-LC/MS/MS, and we have
shown that DOCK180 localizes to the endosome with SNX5
(summarized in Figure 8). Knockdown of either SNX5 or
DOCK180 perturbed the CI-MPR transport from early en-
dosome to TGN, suggesting that the binding is physiologi-
cally relevant. For this regulation of CI-MPR transport, we
found that the DHR1 of DOCK180 was sufficient, and thus it
was not necessary for DOCK180 to bind to ELMO, Rac1, or
CRK. SNX5 was found to bind to DHR1 of DOCK180, but
not to those of other DOCK-family proteins. This high spec-
ificity to DOCK180 was surprising in light of previous ob-
servations that most, if not all, DOCK-family proteins share
GEF activity for Rac1 and/or Cdc42 and the affinity to
phosphoinositides (Nishihara et al., 1999; Cote and Vuori,
2002; Watabe-Uchida et al., 2006).
Aberrant CI-MPR transport caused by the knockdown of
either SNX5 or DOCK180 supports our view that DOCK180
regulates the retromer complex via its interaction with SNX5
(Figures 4, 5, and 8). The finding that DHR1 recognition
requires amino acids 169–261 of SNX5, spanning the N-
terminal-linker and the first helix of the BAR domain, may
provide a clue to the molecular mechanism (Figure 3). This
observation suggests that, either directly or indirectly,
DHR1 of DOCK180 may regulate the function of the BAR
domain to deliver CI-MPR properly. The BAR domain has
been suggested to be involved in dimer formation and cur-
vature sensing. A crystal structure study of the BAR domain
from Drosophila amphiphysin has revealed that the BAR
domain conforms to a homo dimer of two kinked rods
arranged at an angle and in the opposite orientation and fits
its banana shape into the curvature of the liposomes (Peter et
al., 2004). Consistent with this observation, SNX1 has been
shown to reside on the tubular elements on the early endo-
somes, forms the dimer, binds preferentially to a highly
curved membrane, and tubulates membranes in vitro (Car-
lton et al., 2004). More recently, SNX5 has been shown to
associate with tubular extensions of the macropinosome
(Kerr et al., 2006) and the SNX1-endosome (Wassmer et al.,
2007), indicating that the SNX5 BAR-domain also possesses
membrane-bending and curvature-sensing capacities. Im-
portantly, we found that DHR1 is sufficient to rescue the
aberrant retrograde transport of CI-MPR in DOCK180-defi-
cient cells (Figure 7, D–F). Thus, it is possible that DHR1-
binding to the BAR domain of SNX5 may change its confor-
mation suitable for the retrograde transport of CI-MPR.
It remains an open question whether the binding of DHR1
to PIP3 is required for its regulation of SNX5. However, the
observation that the RLC mutation in DHR1 ablated binding
to both SNX5 and PIP3 suggests that DHR1 functions as a
molecular glue to recruit the retromer complex from early
endosome to the TGN or late endosomes (Figure 8). Notably,
DHR1 binds to PI(3,5)P2 as efficiently as PIP3 (Cote et al.,
2005). In contrast to PIP3, which is primarily found in the
plasma membrane, PI(3,5)P2 is enriched at the late endo-
some (Di Paolo and De Camilli, 2006). Recently, it was
revealed that some fraction of MPR is transferred from early
to late endosomes in a syntaxin 10-dependent manner
(Ganley et al., 2008). Therefore, we could speculate that
DHR1 might play a role in retrograde transport by targeting
the SNX5 complex to the late endosome. In vitro binding of
Figure 6. Rac1 does not affect steady state CI-MPR distribution.
(A) CD8-CI-MPR–expressing HeLaM cells were treated with 1 nM
of SOS2-, SNX5-, or Rac1-targeted siRNA oligonucleotides indicated
at the top. Forty-eight hours later, proteins were examined by
Western blotting with antibodies against SOS2, SNX5, Rac1, and
pan-ERK as indicated to the right. (B) In parallel, cells were pro-
cessed and analyzed as in Figure 4, C and E. Percentage of cells with
dispersed CI-MPR was calculated, and mean  SD from three
independent experiments is shown.
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the retromer complex in the presence of DHR1 to the reconsti-
tuted liposomes will provide the details of these interactions;
however, due to the insolubility of the recombinant DHR1 in E.
coli, this hypothesis has not been tested at this moment.
It has been reported that the constitutive-active form of
Rac1 inhibits the internalization of transferrin and EGF re-
ceptors from the clathrin-coated pit (Lamaze et al., 1996).
However, we could not observe the effect of Rac1 knock-
down in the transport of CI-MPR at the steady state (Figure
6). This discrepancy suggests that Rac1 regulates the trans-
port from plasma membrane to early endosome but not
from early endosome to TGN. Growing evidence suggests
that the BAR domain-mediated binding of Arfaptin to Rac1
regulates membrane ruffles (Tarricone et al., 2001) and that
the BAR-like domain-containing proteins, such as FBP17,
promotes invagination from the plasma membrane, which is
regulated in an actin polymerization-dependent manner
(Habermann, 2004; Itoh et al., 2005). In contrast, it has not
been extensively studied that actin polymerization is re-
quired for the fission from endosomes, suggesting the pos-
sibility that tubulation and fission at the endosomes might
be independent of Rac1-triggered actin reorganization. In
cells depleted of SNX5 or DOCK180, the internalization of
CD8-CI-MPR from the cell surface membrane was not af-
fected, whereas its transport to TGN was impaired (Figure
5), suggesting that the SNX5-DOCK180 complex functions in
the endosome-to-TGN trafficking. Importantly, however,
this model does not necessarily exclude the role of
DOCK180-induced Rac1 activation in the plasma mem-
brane-to-early-endosome transport of CI-MPR and other
cargos. In fact, the effect of DOCK180 deficiency on Rac1
activation is likely to be compensated by the other DOCK-
family proteins, all of which activate Rac1 and/or Cdc42. In
clear contrast, only DOCK180 binds to SNX5 (Supplemental
Figure 7. DHR1 of DOCK180 is sufficient for CI-MPR transport. (A) 293F cells were transfected with plasmid encoding proteins indicated
at the top and analyzed as described in Figure 1A. WT and RLC denote the wild type and RLC mutant, respectively. The corresponding bands
to SNX5, GST, GST-DHR1-WT, and GST-DHR1-RLC are denoted to the right. (B) Plasmids for the Venus-tagged proteins indicated at the top
were transfected into 293T cells. Forty-eight hours later, cells were collected and lysed and processed further as described in Materials and
Methods. The proteins bound to the beads and total cell lysate (denoted as “bound to PIP3-beads” and “total lysate” at the bottom) occur in
the left and right panels, respectively, which were blotted with anti-GFP antibody. The results are representative of three independent
experiments. (C) 293F transiently expressing EGFP-DOCK180, FLAG-SNX5, or both, as indicated to the left, were collected and lysed. Proteins
were incubated with beads conjugated by the lipids indicated at the top, and bound proteins were analyzed using SDS-PAGE and Western
blotting by antibody against FLAG and GFP. White and black arrowheads indicate EGFP-DOCK180 and FLAG-SNX5, respectively, as
denoted to the right. (D–F) CD8-CI-MPR–expressing HeLaM cells were microinjected with various combinations of plasmids for proteins and
shRNA indicated at the bottom. Forty-eight hours later, cells were processed and analyzed as in Figure 4, C and E. The mean  SEM from
three independent experiments are shown.
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Figure S1B). This specificity may be the reason why we
could observe the effect of DOCK180 deficiency only in the
early-endosome-to-TGN transport.
In summary, we found that DOCK180 regulates transport
of CI-MPR via SNX5 binding. In addition to CI-MPR, a wide
range of cargo molecules are transported by the retromer-
mediated retrograde machinery, e.g., sortilin and many bac-
terial exotoxins such as Shiga and cholera toxins (Seaman,
2004; Bujny et al., 2007). Although delivery of these toxins is
governed basically by the retromer complex, the degree of
SNX dependency varies among the toxins (Bujny et al., 2007).
Therefore, examination of the fate of these cargos in SNX5-
or DOCK180-deficient cells would further dissect the role of
the SNX5-DOCK180 complex in the early-endosome-to-
TGN retrograde transport.
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